Therefore, based on this information, in order to assess the possibility of using Lf in the clinical COVID-19 treatment, we tested its antiviral activity in in vitro experiments to verify whether its activity was associated with the binding of SARS-CoV-2 particles and/or of mammalian cells, similarly to what observed for other viruses (Berlutti et al., 2011; Wakabayashi et al., 2014). This evidence concerns the gene LTF and COVID-19.